GB751767A - Improvements in antitussive compositions - Google Patents

Improvements in antitussive compositions

Info

Publication number
GB751767A
GB751767A GB1315/54A GB131554A GB751767A GB 751767 A GB751767 A GB 751767A GB 1315/54 A GB1315/54 A GB 1315/54A GB 131554 A GB131554 A GB 131554A GB 751767 A GB751767 A GB 751767A
Authority
GB
United Kingdom
Prior art keywords
analgesic
isomethadone
methadone
hydrochloride
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1315/54A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of GB751767A publication Critical patent/GB751767A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Abstract

An antitussive composition which may take the form of powders, tablets, capsules, syrups, or elixirs, comprises a potent analgesic and as an analgesic antagonist, N-allylnormorphine, N-allylnorcodeine, N-allyldihydronormorphinone, N-allyldihydronorcodeinone, or a mixture thereof, which may be present from 0,1 to 5,0 parts for each part by weight of the analgesic. Examples of the analgesic are codeine, morphine, dihydromorphine, dihydrocodeine, dihydromorphinone, dihydrocodeinone, diacetylmorphine, d, l-isomethadone, l-isomethadone, d, l-methadone, l-methadone, 3-hydroxy-N-methylmorphinan 6-methyl-D 6-desoxymorphine, ethylmorphine, N-methyl-4-phenyl-4-carbethoxypiperidine hydrochloride and hydroxydihydrocodeinone. The analgesic and antagonist may be present as the free base or as the acid addition salt e.g. sulphate, phosphate, citrate, hydrochloride or hydrobromide. Diluents which are mentioned are lactose, sucrose, starch, magnesium stearate, potassium guaiacolsulphonate, glycerine, ethyl alcohol, and simple syrup.
GB1315/54A 1953-01-21 1954-01-15 Improvements in antitussive compositions Expired GB751767A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US751767XA 1953-01-21 1953-01-21

Publications (1)

Publication Number Publication Date
GB751767A true GB751767A (en) 1956-07-04

Family

ID=22124051

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1315/54A Expired GB751767A (en) 1953-01-21 1954-01-15 Improvements in antitussive compositions

Country Status (1)

Country Link
GB (1) GB751767A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
EP0315332A1 (en) * 1987-10-27 1989-05-10 Richardson-Vicks, Inc. Antitussive liquid compositions containing phenol
US7682633B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US8685443B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
EP0315332A1 (en) * 1987-10-27 1989-05-10 Richardson-Vicks, Inc. Antitussive liquid compositions containing phenol
AU624793B2 (en) * 1987-10-27 1992-06-25 Richardson-Vicks Inc. Antitussive liquid compositions containing phenol
US8685443B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US8685444B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US7682633B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US7682634B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8846104B2 (en) 2006-06-19 2014-09-30 Alpharma Pharmaceuticals Llc Pharmaceutical compositions for the deterrence and/or prevention of abuse
US8877247B2 (en) 2006-06-19 2014-11-04 Alpharma Pharmaceuticals Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition

Similar Documents

Publication Publication Date Title
Casy et al. Opioid analgesics: chemistry and receptors
GB841697A (en) Analgesic compositions
EP4253531A3 (en) Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof
IE44562L (en) Pharmaceutical compositions of addicting agents having¹reduced addiction liability
GB1390772A (en) Oral narcotic composition
BRPI0613769A2 (en) solid narcotic drug dosage formulations having improved buccal adsorption
CA2229597A1 (en) Oral fast-dissolving compositions for dopamine agonists
GB751767A (en) Improvements in antitussive compositions
HUE033670T2 (en) Inhibitor of analgesic tolerance
Jacob et al. Opioid antagonists, endogenous ligands and nocioception.
GB1183403A (en) Antitussive Medicament with Prolonged Effect
Fujimoto et al. Narcotic antagonist activity of several metabolites of naloxone and naltrexone tested in morphine dependent mice
JPS51142544A (en) An anodyne comprising an indole acetic acid derivative,and a narcotic onarcotic or narcotic competitive analgestic compound as chief compone nts
GB769517A (en) Analgesic compositions
GB894609A (en) Tannates of morphine alkaloids
Ronai et al. Orientation of the oxygen atom at C-6 as a determinant of agonistic activity in the oxymorphone series.
GB2014141A (en) 8???-ethyl- and 8???-methyl-4,5??? epoxymorphinan-6-one compounds
Butz et al. Pharmacokinetics and O-dealkylation of morphine-3-alkyl ethers in the rat. A radioimmunoassay study
ES348435A1 (en) Hydrogenated ergot alkaloid compositions and methods of using same
Albin et al. Tetrahydroaminoacridine antagonism to narcotic addiction.
Casy The structure of narcotic analgesic drugs
Milne et al. One way cross tolerance from morphine to nantradol-A potent, non-opioid analgetic
McKenzie Some pharmacological properties of pyrrolizidine alkaloids and their relationship to chemical structure.
GB854354A (en) A new and improved morphine derivative
Gambino et al. Agonist and antagonist properties of some benzomorphans on nociceptive reaction and intestinal transit in rats